Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?

Mario Roselli, Vittore Cereda, Maria Giovanna di Bari, Vincenzo Formica, Antonella Spila, Caroline Jochems, Benedetto Farsaci, Renee Donahue, James L Gulley, Jeffrey Schlom, Fiorella Guadagni, None, Effects of conventional therapeutic interventions on the number and function of regulatory T cells. OncoImmunology. ,vol. 2, ,(2013) , 10.4161/ONCI.27025

Julie Vincent, Grégoire Mignot, Fanny Chalmin, Sylvain Ladoire, Mélanie Bruchard, Angélique Chevriaux, François Martin, Lionel Apetoh, Cédric Rébé, François Ghiringhelli, 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Cancer Research. ,vol. 70, pp. 3052- 3061 ,(2010) , 10.1158/0008-5472.CAN-09-3690

Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara, Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 26, pp. 3543- 3551 ,(2008) , 10.1200/JCO.2007.15.0375

Alan Sandler, Robert Gray, Michael C. Perry, Julie Brahmer, Joan H. Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H. Johnson, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer The New England Journal of Medicine. ,vol. 355, pp. 2542- 2550 ,(2006) , 10.1056/NEJMOA061884

Zhi-Chun Ding, Xiaoyun Lu, Miao Yu, Henrique Lemos, Lei Huang, Phillip Chandler, Kebin Liu, Matthew Walters, Antoni Krasinski, Matthias Mack, Bruce R. Blazar, Andrew L. Mellor, David H. Munn, Gang Zhou, Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1–PD-L1 Axis Cancer Research. ,vol. 74, pp. 3441- 3453 ,(2014) , 10.1158/0008-5472.CAN-13-3596

Roy S Herbst, Rafat Ansari, Frederique Bustin, Patrick Flynn, Lowell Hart, Gregory A Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula O'Connor, John Hainsworth, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial The Lancet. ,vol. 377, pp. 1846- 1854 ,(2011) , 10.1016/S0140-6736(11)60545-X

Mark A. Socinski, Igor Bondarenko, Nina A. Karaseva, Anatoly M. Makhson, Igor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, Hui Zhang, Jose L. Iglesias, Markus F. Renschler, Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial Journal of Clinical Oncology. ,vol. 30, pp. 2055- 2062 ,(2012) , 10.1200/JCO.2011.39.5848

Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesús Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H Zimmermann, Carla Visseren-Grul, Cesare Gridelli, None, PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 31, pp. 2895- 2902 ,(2013) , 10.1200/JCO.2012.47.1102

Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, None, Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 375, pp. 1823- 1833 ,(2016) , 10.1056/NEJMOA1606774

Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi, Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study The Lancet Oncology. ,vol. 17, pp. 1497- 1508 ,(2016) , 10.1016/S1470-2045(16)30498-3